Redx Pharma PLC (AIM:REDX) will present a poster on its lead fibrosis asset RXC007 at the upcoming International Colloquium on Lung and Airway Fibrosis between October 1-5 in Reykjavik, Iceland.
The poster will present RXC007 preclinical efficacy data across fibrosis models and Phase 1 data for single and multiple ascending dose studies in healthy male volunteers, the clinical-stage biotechnology company that focuses on treating cancer and fibrotic disease said.
RXC007, Redx's lead fibrosis asset, is a highly selective ROCK 2 inhibitor, which is expected to enter Phase 2a clinical studies for lead indication idiopathic pulmonary fibrosis (IPF) in 2022, following encouraging Phase 1 safety and pharmacokinetic data.